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Abstract
Pancoast tumours are now amenable to multimodality treatment with an acceptable survival. This is because tri-
modality treatment improves tumor sterilization and hence outcome. Moreover the development of an anterior
approach to access the tumor, further improved the technical challenges for a sound resection.
The Anterior-manubrial sternal approach was described more than a decade ago and although this method facili-
tates better exposure of the extreme apex of the lung, brachial plexus and subclavian vessels, its popularity has not
reached high levels. We felt that by re-addressing this topic we would stimulate reconsideration of the anterior
approach.
Introduction
Pancoast syndrome is due to lesions extending to the
superior thoracic inlet. Specific symtomatology mainly
due to brachial plexus invasion accounts for the major-
ity of those cases [1-3].
Pancoast tumour is a tumour of the apex of the lung
with no intervening lung tissue between tumour and
chest wall. Subsequently, there is an involvement of
structures of the apical chest wall above the level of the
second rib. Almost half of the treated cancers are squa-
mous cell carcinomas (45-50%), while the rest are either
adenocarcinomas (36-38%) or undifferentiated large-cell
carcinomas (11-13%). The tumour rapidly involves the
structures of the thoracic inlet & the root of neck. Due
to its localization in the apex of the lung, invasion of
the lower part of the brachial plexus, first ribs, verteb-
rae, subclavian vessels or stellate ganglion, occurs [4].
The classical Pancoast presentation, with shoulder pain
radiating to the ulnar side of the arm and the hand, is
presented in 55 to 60% of the patients. Pain at the ulnar
aspect of the forearm and hand is consistent with T1
involvement; furthermore symptomatology along the
intrinsic hand muscles suggests the C8 root or lower
trunk tumor deposits. Horners syndrome is reported in
up to 30% of the cases.
Although those tumours represent a wide range of
stage IIB to stage IV disease, [IIB (25-27%), stage IIIA
(6-8%), stage IIIB (40-42%) and stage IV (21-23%)] it is
the T3, T4, N0-N1 subgroup of this spectrum that
could be amenable to surgical intervention [5]. This
subgroup of patients (less than 5% of Bronchogenic Car-
cinomas) however, is difficult to be treated surgically
due to the location of the tumour and the complex
anatomy of the area involved [6]. Historically, Pancoast
tumors have been associated with high rates of incom-
plete resection, local recurrence, and death.
Pancoast tumours were thought to be located poster-
iorly and early attempts to resect those tumors were
approached solely from the back. A percentage of these
lesions might also be located at the front, with vascular
rather than neuro-vertebral involvement. Various
reports suggested spinal involvement in 15%, brachial
plexus in 15% and subclavian vessels in 6% of the cases
[7]. Therefore surgeons treating these cancers should be
able to be familiar and adapt with the various
approaches.
An understanding of the posterior location of neural
structures and somewhat anterior location of vascular
structures is important for adequate operative planning.
It is worth noted that the popularity of this approach
has not reached high levels of acceptance in Britain
* Correspondence: hparissis@yahoo.co.uk
1Cardiothoracic Dept, Royal Victoria Hospital, Belfast, Northern Ireland
Full list of author information is available at the end of the article
Parissis and Young Journal of Cardiothoracic Surgery 2010, 5:102
http://www.cardiothoracicsurgery.org/content/5/1/102
© 2010 Parissis and Young; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
(First National Thoracic Surgery Activity & outcomes
Report from the Society for Cardiothoracic Surgery in
Great Britain & Ireland/2008). Our experience consists
of a handful of cases therefore with the present article
we attempt to elaborate on the anatomy, initial assess-
ment, and surgical approaches with an emphasis on the
modified anterior approach for this form of cancer.
The evolution of the treatment
For more than 40 years the treatment of Pancoast
tumors has centered on a bimodality regimen consisting
of preoperative external beam radiotherapy followed by
surgery. Trimodality treatment however with the addi-
tion of platinum based chemotherapy regimes has
become currently the standard treatment, in order to
achieve additive anti-tumour effects (chemotherapy as
radiation sensitizer). According to Wright et al [8]
induction Chemoradiotherapy (CT/RT) can be adminis-
tered with low morbidity, a higher complete resection
rate, a high pathologic response rate, a reduced locore-
gional recurrence rate and improved survival. Further
improvement in radiotherapy with the advent of 3-
dimensional conformal radiotherapy, the total radiation
dose that could be safely delivered was not anymore
constrained by dose-limiting toxicities upon the nearby
organs.
Careful patient selection for trimodality treatment, on
the basis of staging and comorbidity, is of vital impor-
tance in the treatment of Pancoast tumours. Neverthe-
less only 30% of M0 patients with Pancoast tumors were
eligible for combined treatment according to Pourel
et al [9].
Not only operapability (patient fitness to surgery) but
also ability to resect the tumour is of a major impor-
tance bearing in mind the difficulty of access, the
crowded anatomy of this region and the tendency of the
tumors in this area to involve important adjacent struc-
tures. As per the same group [9], following CT/RT, 67%
of the patients were amenable to thoracotomy. The
resection rate, which had remained unchanged at
approximately 50% for almost 40 years with conven-
tional preoperative radiotherapy, was improved to above
70% in SWOG [10] and JCOG [11] studies.
Preoperative radiotherapy was part of the standard
treatment, but a recent prospective phase II study
(Southwest Oncology Group 9416, INT 0160), [10] sug-
gests that preoperative concurrent CT/RT (platinum-
based chemotherapy and 45 Gy of radiotherapy)
improves the rate of complete resection, local recur-
rence, and intermediate-term survival.
Like wise, the Japan Clinical Oncology Group JCOG
trial 9806 [11] in a prospective report concluded along
similar lines. Furthermore, Kwong et al [12] reported
that high dose radiotherapy targeting up to 60 Gy
(rather than 45 Gy) can be given in the neoadjuvant set-
ting; it is successfully tolerated and associated with
improved resection rate.
Surgical considerations
The limited access and poor visualization of the thor-
acic inlet is due to: 1) the unique course of the upper
ribs downwards and outwards that render the neuro-
vascular bundle inaccessible to posterior approaches,
2) the musculature of the area and also 3) the over-
lapping bulky pectoral-shoulder girdle with the clavi-
cle and the manubrium to further restrict access from
the neck. These anatomical idiosyncrasies create a
hostile but challenging environment for the thoracic
surgeon.
The main goal for cure is to achieve local control of
the disease and aim for relapse-free, metastasis-free out-
come. Local control is obtained by removing the upper
lobe, chest wall and invaded structures (subclavian
artery or vertebra), aiming for R0 resection margins.
Radically resected cases yield better survival whereas R1
resections are associated with high incidence of local
and distal recurrences.
Involvement of the vertebral body or brachial plexus,
once considered unresectable is nowadays amenable to
advanced techniques of spinal reconstruction and should
be planned jointly with a spine neurosurgeon.
Finally, according to recent reports [10,11] the rate of
R0 resection could be above 85%, with the use of tri-
modality protocols.
Contraindications for surgery would be due to metas-
tasis, invasion of the brachial plexus above C7 & inva-
sion of the spinal canal. Resection of the T1 nerve root
is usually well tolerated, but removal of the C8 root or
lower trunk of the brachial plexus leads to loss of hand
and arm function. N2 disease, is a relative contraindica-
tion and some groups enroll those patients after
extended hilar radiation.
As per JCOG [11] rib involvement occurs in 77.2% of
the patients (usually 3 ribs or more), vertebra involve-
ment in 10.5% of the patients, and major vessels in
5.3%. T1 involvement is the commonest root involved in
up to 85% of the cases.
Downstaging
According to Wright et al [13] marked difference in
pathologic response based on the induction therapy is
favoring CT/RT.
Surgical resection of Pancoast tumors after neoadju-
vant high-dose CT/RT was carried out in 40.5% of
patients according to Kwong et al [12].
Pathological downstaging although it does not corre-
late with the radiological appearance [10] is reported to
be impressively above 30% in various series.
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As per Pourel et al [9], pathological complete response
was observed in 39.5% of the patients, necrosis of
tumoral tissues between 50% and 95% in 22.5% and less
than 50% in 38% of the patients. Along the same lines,
JCOG reported [11] pathologic downstaging of the
tumor in 40% of the patients; No residual viable tumor
cells in the resected specimens, was achieved in 16% of
the treated patients. Finally SWOG [10] summarized
that pathologic no residual microscopic tumor was seen
in one third of the resected specimens and minimal
microscopic residual (few scattered tumor foci within a
mostly necrotic or fibrotic mass), was observed in one
third of the resected specimens.
Surgical Approaches
Posterior approach (Paulson)/posterolateral-paraverteb-
ral thoracotomy: This is an extension of the conven-
tional postero-lateral thoracotomy; the incision is
extending around the tip of the scapula, then it continu-
ous upwards and further midway between the posterior
edge of the scapula and the spinous processes, up to the
level of C7. By taking the scapula of the chest wall this
incision allows good exposure of the posterior chest
wall, including the transverse processes, the vertebrae
and the roots of the thoracic nerves and the plexus [14].
Never the less the exposure of the neurovascular struc-
tures are limited. This is due to the fact that brachial
plexus and vascular structures often lie above the tumor
mass and access to such structures, is significantly lim-
ited using approaches from below.
According to Vanakesa et al [15], Posterior approach,
does not provide adequate access to the many important
structures which may be involved by apical chest tumors
of bronchogenic origin. This restricted access may be
one of the reasons for the high rate of incomplete resec-
tions [16] and high surgical morbidity and mortality
using this approach [13].
The anterior-cervical entry [17] proved to be the
answer to the problem of limited exposure. It appears to
be the optimal approach to anterior lung apex or first
rib lesions [18].
We would facilitate a case like the one presented in
Figure 1 by using an Anterior-manubrial-sternal
approach for access.
Accurate and thorough staging & re-staging (Radiolo-
gical response is defined according to the RECIST cri-
teria [19]) following neo-adjuvant treatment is necessary
prior to surgery (see Figure 2) and typically includes
CT-PET and magnetic resonance imaging (Contrast-
enhanced MRI of Chest and Brain). MRA is a noninva-
sive diagnostic method complementary to MR imaging
for detecting vascular involvement in bronchogenic car-
cinoma with Pancoast syndrome [20].
Root of neck anatomy as in Figure 3 is depicting care-
fully the relationship of the most important neurovascu-
lar structures to the scalene musculature and the first
rib. The anterior and middle scalene muscles are
attached to the first rib and can be used as landmarks:
in front of the anterior scalene muscle situated the sub-
clavian and internal jugular veins and the sternocleido-
mastoid and omohyoid muscles.
The subclavian artery, the trunks of the brachial
plexus, and the phrenic nerve are emerging above the
lateral part of the first rib between the anterior and
middle scalene muscles. The nerve roots of the brachial
plexus, the stellate ganglion, and the vertebral column
are situated behind the middle scalene muscle.
The Surgical steps (Figure 4)
We favor a modified Dartevelle approach [17] an
L shaped incision at the anterior edge of Sterno-cleido-
mastoid (2). Division of the upper sternum extended
into 2nd intercostal space. This is a modified access
something between Grunenwald [21] and Klima et al
[22] approach. Grunenwald has described a transmanu-
brial approach, which avoids division of the clavicle.
Klima and colleagues suggested extending the L-shaped
section of the manubrium down to the first intercostal
space. We prefer to divide the sternum down to the
angle of Luis and then extend the incision horizontally
along the 2nd intercostal space, thus allowing the sur-
geon to lift the clavicle, subclavian muscle, and trans-
ected part of the manubrium and superior body of the
sternum without dividing the first costal cartilage and
ligament. The internal mammary artery is encountered
and divided during the horizontal intercostal incision.
Mobilisation & excision of the supraclavicular fat pad
(3), allows exposure of the structures at the thoracic
inlet; further division of the subclavius, omohyoid with
preservation of the accessory nerve is carried out.
The distal part of the jugular veins is divided to
expose the subclavian and innominate veins. If the sub-
clavian vein is affected then it is resected. Following
this, the scalenus anterior muscle is divided by taking
care to preserve the phrenic nerve (4) & (5). The subcla-
vian artery is mobilized by, dividing most of its
branches. Care is taken to preserve the vertebral artery
and resection of the vessel is done only if it is involved
with the tumor and no substantial extracranial occlusive
disease can be detected on preoperative Doppler
ultrasound.
If the subclavian artery is taken up by tumor, the
affected portion is resected and reconstructed, usually
with a 6-8 mm PTFE vascular graft. Small dose of
heparin is usually administered during vascular
clamping.
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Figure 1 CXR, CT Chest imaging, MRI and bone scan of a Pancoast tumor of a 47 yrs old female, Ex smoker (25 cigs per day up to 13
years ago). Six weeks history of shoulder pain radiating to the median aspect of the right arm. CXR mass at apex of right chest. Percutanteous
Biopsy NSCLC. PMH: Hysterectomy for Ca cervix 1996 - no evidence of recurrence. Clinical examination fullness in right supra-clavicular fossa
Figure 2 Staging algorithm for patients prior to resection of a Pancoast Tumor. MRI of the thoracic inlet may yield further information’s on
the status of vertebra involvement
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Following anterior traction of the subclavian artery,
the scalenus medius muscle comes into good view. The
muscle is divided above its insertion on the first rib, giv-
ing access to the branchial plexus. Familiarity with the
anatomy of the plexus is important. At this stage, the
anterior surface of the vertebral bodies of C7 and T1
are in view. The sympathetic chain and stellate ganglion
are lying in front of the anterior surface of the vertebral
bodies of C7 and T1. The C8 and T1 nerve roots are
visualized and dissected medially up to the lower trunk
of the brachial plexus. The C8 nerve component of the
plexus is preserved if possible, for better functional out-
come of the upper limp.
Care is taken then, to access tumor invasion and plan
with the neurosurgeon the “spinal component” of the
operation.
Chest wall resection is carried out by dividing the first
2-3 ribs at the sternal - costochondral junction following
by disarticulation of the ribs from the transverse pro-
cesses at the back. The last part of the resection consists
of the upper Lobectomy (6). The access to perform a
lobectomy and mediastinal lymph node clearance
through the anterior incision is usually limited, therefore
like others [23] we perform a traditional posterolateral
thoracotomy through the 5th IC space. Routine coverage
of the bronchial stump with an intercostal or serratus
muscle flap is advocated by some groups [12] to coun-
teract any potential damage on the stump from the
neoadjuvant radiation. Chest wall reconstruction may be
necessary in up to 40% of the cases [23].
For Pancoast carcinomas affecting the spine, a poster-
ior midline approach can be added by a neurosurgeon,
for multilevel unilateral laminectomy [24], nerve root
division inside the spinal canal, and vertebral body divi-
sion along the midline. The tumor then is removed en
bloc with the lung, ribs, and vessels through the poster-
ior incision. Fixation of the spine is mandatory.
The advantages of the Anterior-Cervical approach
According to Machiarini et al [25] one of the major
advances in the treatment of Pancoast tumors has been
the introduction of anterior approaches for resection.
These approaches increase the likelihood of complete
resection and permit resection of tumors that were pre-
viously considered technically unresectable [26].
Furthermore anterior approach facilitates:
1) Direct visualization of major structures (eg. Subcla-
vian artery, superior vena cava) thus allowing control
and elective sacrifice of the artery if necessary and
reconstruct directly to a safe outcome.
2) Excellent exposure of the brachial plexus, sympa-
thetic chain, and stellate ganglion.
3) Freedom to carry out hemi-vertebrectomy if the
anterior body of the vertebrae are involved.
4) Resection of the lower parts of the Brachial plexus,
especially of the C8, T1 roots; however T1 root
Figure 3 Root of neck anatomy, depicting carefully the relationship of the most important neurovascular structures to the scalene
musculature and the first rib.
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resection results in diffuse weakness of the intrinsic
muscles of the hand, whereas resection of the C8 nerve
root of the lower trunk of the brachial plexus results in
permanent paralysis of the hand muscles
5) Optimal access, for resection of the chest wall
6) Oncological clearance of the structures of the Thor-
acic inlet, because the tumor is the last to be encountered.
7) Lower morbidity than the posterior approach
Moreover as per Vanakesa et al [15] the cervical-
trans sternal approach has several advantages, chiefly
that of avoiding disfigurement and loss of function of
the pectoral girdle, whilst providing excellent exposure
of the brachial plexus, sympathetic chain, and stellate
ganglion. Such an approach results in a short post-
operative stay (3-6 days), and yet allows extension as
per Grunenwald [21], or by a high, anterior thoracot-
omy if necessary.
Disadvantages of the Anterior-Cervical approach
Removal of transverse processes and the head of the ribs
in order to disarticulate them, could be difficult with the
anterior access; furthermore more posterior seated
tumors with vertebra involvement may require a compli-
mentary posterior incision.
Figure 4 Step by step resection of a Pancoast tumor through an Antero-cervical approach. Incision at the anterior edge of Sterno-cleido-
mastoid (a). Division of the upper sternum extended into 2nd intercostal space(b). Mobilisation-Excision of supraclavicular fat pad (c). Exposure of
the structures at the thoracic inlet by dividing the subclavius, omohyoid with preservation of the accessory nerve. Division of the Scalenus
anterior with preservation of the phrenic nerve (d) & (e). Right upper Lobectomy (f): can be performed through the neck incision or a
posterolateral thoracotomy.
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There are concerns about functional and aesthetic
results with the transclavicular approach, which includes
removal of the medial half of the clavicle.
Finally, the need to perform an additional posterolateral
thoracotomy for the lobectomy and mediastinal node
clearance could be seen as a factor that negates any
advantage of the routine use of the anterior-manubrial
sternal approach.
Results
Unfavorable outcome is due to incomplete resection and
life-threatening complications.
Current reports are quoting perioperative mortality
not higher than for any other lung resection [10,11].
Adverse prognostic factors, are including the presence
of mediastinal nodal metastases (N2 disease), spine or
subclavian-vessel involvement (T4 disease), and limited
resection (R1 or R2) [27-29]. Along similar lines, Gins-
berg et al. [30] found Horner’s syndrome, N2/N3 dis-
ease, T4 disease and incomplete resection, in general, to
be adverse prognostic factors. Okubo and associates [16]
found that incomplete resection particularly tumour
invasion to the brachial plexus, influenced the prognosis.
Recurrence
With bimodality regimes the local recurrence rates were
reported to be above 70% [7,13]. Despite the advent in
treatment regimes, local recurrence still occurs in about
40% of the patients [29]; it is expected that local recur-
rence rate is higher in patients with T4 disease because
complete resection can be achieved in less than half of
the patients with c-T4 disease [11]. More specifically
[27] complete resection rate was achieved in only 64%
of tumour stage T3 and nodal stage N 0 and 39% of
T4N0 tumours. It is apparent however, that locoregional
relapse is predominant in R1-2 resections, whereas dis-
tant recurrence is frequent in R0 resections.
One would expect that a shift in the trend of clinical
recurrences towards distant metastasis is to be currently
expected because of the fact that trimodality treatment
facilitates better R0 resection. As per Pourel et al [9] the
most frequent site of relapse was distant metastasis in
66% of the patients, (mainly brain) with the locoregional
recurrence rate been 18%. Likewise King et al [13]
reported brain metastasis in 25% and local recurrence
rate in 19% of the cases. A small series that had bimod-
ality treatment however had an incidence of locoregional
recurrence of 17.2% [8]
Survival has been extensively reviewed by Attar et al
[31]. Overall survival at 5 years after surgery was 46%
for T3N0, 13% for T4N0, and 0% for lesions with N2
disease [27]. Particularly noteworthy [11] was the repro-
ducibility of the favorable survival data, with a 5-year
overall survival rate of 44% in the United States trial
(SWOG) and 56% in JCOG trial, which were clearly
superior to the historical value of 30%.
Future
In the future new neoadjuvant regimes including aggres-
sive protocols of accelerated radiotherapy would poten-
tially increase the pool of surgical candidates from
patients diagnosed with a Pancoast tumor (currently
23% of the patients as per Kappers et al [7]). However,
several questions still remain unresolved:
1) The role of PET-CT in restaging tumors (eg. The
role of “late wash out” images in differentiating between
inflammation and residual tumor) following neoadjuvant
treatment; Schmuecking et al. [32] have shown that
metabolic response after induction CT/RT evaluated
within 1 week following its completion, is highly predic-
tive of pathological response.
2) What is the significance and implications of ipsilat-
eral supraclavicular lymph node disease: The argument
being that these nodes are in close vicinity of the
tumour and therefore could have the characteristics of
the biological behaviour of “N1 disease”.
3) Recruiting patients with N2 disease: The argument
being that inclusion of the hilar and mediastinal nodes
in the irradiation field promotes downstaging. Kwong et
al. [12] did not exclude patients with positive mediast-
inal nodes from trimodality treatment and found no dif-
ference in survival. In most papers, however, results of
patients with persistent N2 disease turned out to be
clearly inferior to those of patients with N0/1 only. On
the other hand, no clinical trial has yet compared var-
ious trimodality treatment regimes for patients with N2
disease.
4) The role of prophylactic cranial irradiation: Due to
good locoregional control with trimodality treatment,
distant metastases now represent the most common site
of failure. Furthermore, the incidence of brain metastasis
as a first site of recurrence in Pancoast tumour is
between 15-30% [23,33]. The negative impact of brain
metastasis on survival has to be weighed against the
risks benefits ration of the impact of prophylaxis with
radiation to the brain
5) The role of high dose of RT (up to 60 Gy): Are
there specific subgroups (eg. for patients with clinical
T4 disease complete resection is feasible in less than
50% of the cases) that they would benefit
6) The role of Adjuvant postoperative chemotherapy:
distant metastases now represent the most common site
of failure following treatment for Pancoast tumors
therefore preventing distant metastasis has now become
the challenge in the treatment of these patients. Large
randomized trials concluded a 5–15% survival benefit at
5 years of adjuvant chemotherapy in patients with radi-
cally resected stages I–IIIA NSCLC [34,35] However,
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many patients with Pancoast tumors may not tolerate
more extensive treatment. Moreover Martinod et al.
[36] reported that preoperative radiotherapy significantly
improved the 5-year survival for stage IIB–IIIA, while
postoperative radiotherapy and chemotherapy did not
significantly alter survival. The survival benefit with the
use of the anterior approach for the same stage of Pan-
coast tumors versus the posterior approach also remains
to be seen.
Conclusion
Pancoast tumors represent a small percentage of Lung
cancer population (1-5%). Due to poor performance sta-
tus and/or advanced tumor stages, only 30-40% [7,13] of
those patients are eligible to be enrolled in multimodal-
ity protocols of treatment.
Careful patient selection and adherence to protocols
enables Clinical groups to get an impression of the efficacy
of an intervention and to compare results between studies.
No single surgical approach however, provides the
best access to all heterogeneous tumors of the thoracic
inlet. What probably provides the most favorable out-
come would be a team approach, where the thoracic
surgeon coordinates with an experience neuro-spinal
surgeon, in a background of limited disease that is
responding well to neoadjuvant chemoradiotherapy.
Finally, the thoracic surgeon must be familiar with the
potential advantages that the anterior approach offers
under given circumstances. This knowledge enables the
thoracic surgeon to explore new avenues and exciting
challenges. Darteville’s approach and the various modifi-
cations are technically demanding, however, once the
anatomy has been appreciated, direct visualization of the
major structures of the Thoracic inlet aids to facilitate
complete oncological clearance. Finally, whether the
anterior approach results in less locoregional recur-
rences and possibly better 5 year survival, remains to be
tested.
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